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OBJECTIVES The purpose of this study was to investigate the utility of cardiac troponin T and troponin I
for predicting outcomes in patients presenting with suspected acute coronary syndromes and
renal insufficiency relative to that observed in similar patients without renal disease.
BACKGROUND Cardiac troponin T and troponin I have shown promise as tools for risk stratification of
patients with acute coronary syndromes. However, there is uncertainty regarding their cardiac
specificity and utility in patients with renal disease.
METHODS We measured troponin T, troponin I and creatine kinase MB in 51 patients presenting with
suspected acute coronary syndromes and renal insufficiency and in 102 patients without
evidence of renal disease matched for the same peak troponin T or I value, selected from a
larger patient cohort. Blood samples were obtained at presentation to an emergency room 4
hours, 8 hours and 16 hours later. The ability of biochemical markers to predict adverse
outcomes in both groups including infarction, recurrent ischemia, bypass surgery, heart
failure, stroke, death or positive angiography/angioplasty during hospitalization and at six
months was assessed by receiver-operator curve analysis. The performance of both troponins
was compared between groups.
RESULTS Thirty-five percent of patients in the renal group and 45% of patients in the nonrenal group
experienced an adverse initial outcome; over 50% of patients in all groups had experienced an
adverse outcome by 6 months, but these differences were not significant. The area under the
curve (AUC) for the ROC curve for troponin T as predictor of initial outcomes was
significantly lower in the renal group than in the nonrenal group: 0.56 6 0.07 and 0.75 6
0.07, respectively. The area under the curve was also significantly lower in the renal group
compared with the nonrenal group for troponin T as predictor of six month outcomes: 0.59 6
0.07 and 0.74 6 0.07, respectively. The area under the curve was also significantly lower in
the renal group compared to the nonrenal group for troponin I as predictor of both initial and
six month outcomes: 0.54 6 0.06 vs. 0.71 6 0.07 and 0.53 6 0.06 vs. 0.65 6 0.07, respectively.
The sensitivity of troponin T for both initial and six month adverse outcomes was significantly
lower in the renal group than in the nonrenal group at a similar level of specificity (0.87): 0.29 vs.
0.60 and 0.45 vs. 0.56, respectively. Troponin I also exhibited similar differences in sensitivity in
the renal group (0.29 vs. 0.50 and 0.33 vs. 0.40, respectively).
CONCLUSIONS The ability of cardiac troponin T and troponin I to predict risk for subsequent adverse
outcomes in patients presenting with suspected acute coronary syndromes is reduced in the
presence of renal insufficiency. (J Am Coll Cardiol 1999;33:471–8) © 1999 by the American
College of Cardiology
The myocardial contractile proteins, cardiac troponin T
(cTnT) and cardiac troponin I (cTnI) are becoming estab-
lished as important laboratory indicators of myocardial
injury (1–5). In addition to detecting acute myocardial
infarction, troponin T and troponin I may identify high-risk
patients with unstable cardiovascular disease that tend to
suffer subsequent cardiac-related events. The relative clinical
value of cTnT and cTnI in the presence of renal disease,
however, has been questioned. Several studies have ques-
tioned the usefulness of cTnT, in particular, in hemodialysis
patients and patients with renal insufficiency (6–9). Both
small series of patients and anecdotal reports of patients on
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hemodialysis without evidence for cardiac disease have
shown that cTnT may exhibit false positive values (6–9).
However, the prognostic significance of troponin values in
patients with renal disease actually presenting with sus-
pected acute coronary syndromes has not been extensively
studied.
We chose to study a cohort of patients with evidence of
renal insufficiency who presented with suspected acute
coronary syndromes. These cases were matched with a
similar group of patients without renal insufficiency based
either on their peak cTnT or cTnI values. The ability of
cTnT and cTnI to predict both in-hospital and 6 month
outcomes in each cohort was compared.
METHODS
Patients and study protocol. The study was approved by
the Institutional Review Board of the Cleveland Clinic
Foundation. Seven hundred and two patients presenting to
two emergency departments with suspected acute coronary
syndromes during the period December 1995 through
February 1997 were evaluated for entry into the study
groups. Patients were excluded if they had undergone
cardiopulmonary resuscitation within seven days of presen-
tation, angiography or thrombolytic therapy within three
weeks of presentation, or were given vasopressors. Patients
with serum creatinine concentrations equal to, or greater
than 20 mg/L were included in the renal study group. Two
patients without evidence of renal insufficiency were
matched with each case after enrollment was completed
based either on the peak cTnT or cTnI value observed
without consideration of presenting diagnosis, history or
outcomes.
Diagnosis and outcome definitions. Q wave and non-Q
wave myocardial infarctions were diagnosed using the
WHO criteria of demonstration of at least two of the
following: chest pain consistent with cardiac origin, appro-
priate 12-lead ECG changes or characteristic changes in
CK and CK-MB (total CK $220 U/L and RI $4%).
Unstable angina was diagnosed if the patient demonstrated
classic angina at rest or sudden increase in episodes of
previously stable angina with ST segment depression or T
wave inversion in the absence of increased CK-MB. Diag-
noses were confirmed by retrospective review of the medical
record by a blinded investigator. ECG data was subse-
quently evaluated independently by a ECG core facility,
blinded to other data. ECG were classified as positive if
there was a new or unknown left bundle branch block, ST
deviations of 61 mm in 2 contiguous leads (any 2 of 2,3 and
VF or any 2 of I, V1, V5, V6 or any 2 of V1–V4); ECG
were classified as negative if there were no Q waves, no
negative T waves, no ST deviations of 61 mm, no new or
unknown left bundle branch blocks and no new hemiblocks.
All other ECG findings were considered moderate. Adverse
outcomes were defined as death, coronary surgery, recurrent
ischemia, reinfarction, congestive heart failure, and positive
catheterization/intervention. Angiograms were considered
positive if greater than 70% stenosis was present in at least
one major coronary artery. In addition, presenting myocar-
dial infarction was included as an in-house adverse outcome.
Initial hospitalization events were documented by review of
the medical record and confirmation of appropriate indica-
tors by a blinded investigator. Six month outcomes (6.3 6
0.9 months) were documented by phone survey by a blinded
investigator.
Biochemical markers. Blood specimens were obtained at
presentation, 4, 8 and 16 hours later. Total creatine kinase
activity, CKMB, cTnT, cTnI were measured on each
specimen. Routine sampling for CKMB in the existing
clinical protocol did not include a four hour sample and
CKMB was not reported on this specimen. Clinicians
caring for the patients, therefore, were blinded to all
troponin values and the 4 h CKMB value.
Blood samples were collected in evacuated tubes and
centrifuged upon arrival in the laboratory; plasma were
frozen at 270°C until analysis for cTnT and cTnI. Total
CK activity was measured with a kinetic enzymatic method
on a CX7Delta analyzer (Beckman Instruments, Brea,
California). Creatine kinase MB mass (reference range,
#5 ug/L) was determined by immunoassay on an IMx
analyzer (Abbott Laboratories, Abbott Park, Illinois) using
the manufacturer’s reagents. The lower limit of detection for
this assay was 0.7 mg/L.
Cardiac troponin T (reference value #0.1 ug/L) was
measured by second generation commercial ELISA on a
ES300 analyzer (Enzymun Troponin T; Boehringer Mann-
heim, Indianapolis, Indiana) employing streptavidin-coated
tubes and two monoclonal antibodies against cTnT. This
assay is reported to exhibit no signficant cross-reactivity
with skeletal muscle TnT (10). The lower limit of detection
of this assay is 0.02 ug/L.
Cardiac troponin I (reference value #0.6 ug/L) was
quantified by commercial immunoassay using two mono-
clonal antibodies against cTnI on a Stratus II analyzer
(Dade International, Miami, Florida). The detection limit
of this assay is 0.35 ug/L.
Statistical analysis. Continuous variables were compared
with the Mann-Whitney U test due to absence of normal
distributions. Categorial variables were compared with the
Abbreviations and Acronyms
AUC 5 area under the curve
cTnI 5 cardiac troponin I
cTnT 5 cardiac troponin T
CHF 5 congestive heart failure
CK-MB 5 creatine kinase MB
PTCA 5 percutaneous transluminal coronary
angioplasty
ROC 5 receiver operating characteristic
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Fisher-Exact Test or Pearson Chi-square. Receiver-
operator characteristic (ROC) curves were generated and
the area-under-the curve determined by the method of
Hanley and McNeil (11); areas under the curve (AUC) were
compared by determining the z value also according to
Hanley and McNeil (12). Sensitivity and specificity were
evaluated at the upper left inflection point of the ROC curve
(13). Statistical significance was defined as P , 0.05.
RESULTS
Clinical characteristics. The demographics of the study
groups matched by peak cTnT values are shown in Table 1.
The average age of patients was statistically higher in the
renal cohort. Serum creatinine concentrations ranged from
20 mg/L to 148 mg/L (median: 29 mg/L) in the renal
group. Creatinine values exhibited an average change of less
than 1.0 mg/L during the sampling period. Creatinine
values were not correlated cTnT or cTnI values in the renal
group (r 5 20.07, p 5 0.62 and r 5 20.08, p 5 0.60,
respectively). Nine percent of patients in the renal cohort
were dialysis-dependent. The magnitude of change of cTnT
concentration from the initial to the eight h sample was
significantly higher in the nonrenal group (p 5 0.02). Similar
findings were observed in the nonrenal group matched by peak
cTnI values. The median elapsed time between onset of
symptoms and presentation to the emergency department in
the overall cohort was 4.79 hours, the 25% quartile was 2.05
hours and the 75% quartile was 13.45 hours.
Both renal and nonrenal patient groups shown in Table 1
presented with abundant risk factors for cardiovascular
disease. The overall frequency of risk factors in the two
cohorts were not statistically different. A history of hyper-
tension is present in over 90% of renal patients and in 75%
of nonrenal patients. A history of myocardial infarction was
present in 63% of renal and in 36 to 37% of nonrenal
patients, respectively, and this difference was significant.
Initial ECG findings were not statistically different in the
two groups. Diagnoses at time of initial discharge were not
significantly different between the two groups although the
nonrenal group trended towards a greater incidence of acute
myocardial infarction.
The percentage of patients in the renal and nonrenal
groups that experienced an adverse outcome during their
initial presentation or hospitalization was not statistically
different (Table 2). Some patients experienced multiple
events so the total of specific outcomes listed in Table 2 exceed
the number of patients in each group. Interestingly, the rate of
myocardial infarction and reinfarction was significantly higher
in the cTnT matched nonrenal group but, although higher,
failed to reach significance in the cTnI matched group. The
number of patients identified with congestive heart failure
(CHF) was significantly higher in the renal group when
matched by cTnT values and this difference was somewhat less
significant when matched by peak cTnI value.
Overall adverse outcomes by six months were similarly
high in all groups (Table 2). However, the rate of CHF
remained significantly higher in the renal group when
compared to both nonrenal groups. The six month out-
comes are cumulative and include those observed initially
except for the incidence of presenting myocardial infarction.
Table 1. Clinical Characteristics of Groups
Renal
(N 5 51)
Non-Renal
Troponin T
(N 5 102) p* Value
Non-Renal
Troponin I
(N 5 102) p* Value
Age (yr) 70.1 6 12.5 62.4 6 13.4 , 0.001 62.8 6 13.6 , 0.001
Creatinine (mg/dL) 3.83 6 2.68 1.12 6 0.59 , 0.001 1.12 6 0.65 , 0.001
Male/Female 30/21 62/40 0.86 56/46 0.72
History (%) (%) (%)
Myocardial infarction 62.7 37.3 0.003 36.1 0.004
Bypass surgery 37.3 26.5 0.19 27.7 0.34
Diabetes 39.2 26.5 0.15 24.1 0.08
Hypercholesterolemia 37.3 50.0 0.17 45.8 0.37
Hypertension 90.2 75.5 0.03 75.9 0.04
Smoking 60.8 61.8 1.00 61.4 1.00
Initial electrocardiogram
Positive 31.3 29.4 0.70 31.3 1.00
Moderate 45.1 44.1 0.72 40.1 0.71
Negative 13.6 24.5 0.20 26.5 0.19
Diagnosis
Myocardial infarction 7.8 22.5 0.07 18.1 0.22
Unstable angina 23.5 26.5 0.84 26.5 0.84
Other 68.6 50.0 0.14 55.4 0.37
*Comparison to renal group.
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Troponin detection of in-hospital adverse outcomes.
Figure 1 shows the ROC curves for cTnT and cTnI
prediction of adverse in-hospital outcomes in renal and
nonrenal groups. The area under the curve (AUC) for cTnT
was significantly lower in the renal group (0.56 6 0.07 vs.
0.75 6 0.07, p , 0.01). This difference is further evident in
the lower sensitivity (Table 3) found for cTnT at the
indicated inflection point in the nonrenal renal group
compared with the nonrenal group (0.29 and 0.60, respec-
tively) at similar specificities (0.87 and 0.87, respectively).
At the threshold value for cTnT, considered indicative of
myocardial injury (0.1 mg/L), sensitivity and specificity are
considerably lower in the renal group (Table 3). The AUC
for cTnI is also significantly lower in the renal group (0.54 6
0.06 vs. 0.71 6 0.07, p , 0.01). At the optimal threshold,
sensitivity of cTnI for in-house adverse outcomes (Table 3) was
also lower in the renal group compared to the nonrenal group
(0.33 and 0.50, respectively) as was specificity (0.77 and 0.93,
respectively). The optimal threshold shown for cTnI for the
renal group is the lower detection limit of the cTnI assay. At
the more accepted cTnI threshold of 0.6 mg/L, sensitivity was
reduced almost half in the renal group at a similar specificity
(Table 3). The performance of cTnT in the renal and nonrenal
groups as reflected in the ROC AUC was not significantly
different from that of cTnI.
Troponin detection of six month adverse outcomes.
Figure 2 shows the ROC curves for cTnT and cTnI
prediction of adverse 6 month outcomes in both the renal
and nonrenal group. The AUC for the renal group was
again significantly lower than that for the nonrenal group
(0.59 6 0.07 vs. 0.74 6 0.07, p , 0.01). At the upper-left
inflection point of the ROC curve, cTnT exhibited a
sensitivity of 0.45 and specificity of 0.72 in the renal group
at a threshold of 0.10 mg/L and a corresponding sensitivity
of 0.56 and a specificity of 0.87 in the nonrenal group
(Table 3). In a manner similar to cTnT, cTnI demonstrates
a significantly lower AUC in the renal group (0.53 6 0.06
vs. 0.65 6 0.06, p , 0.02). The sensitivity of cTnI in the
renal group at 0.6 mg/L was markedly lower than that seen
in the nonrenal group at a similar degree of specificity
(Table 3). The most accurate threshold value of 0.35 mg/L
for the renal group was the same observed for in-house
outcomes. Because CKMB was not used clinically to assess
6 month outcomes, its ability to predict outcomes was
compared using the cTnT matched nonrenal group and the
ROC curves observed for CKMB (Fig. 2) differ in that the
AUC is not significantly different in the renal and nonrenal
groups. The AUC found for CKMB in the renal group is
higher than either cTnT or cTnI, but the difference fails to
achieve statistical significance.
Evaluation of the predictive value of cTnT and cTnI for
ischemic endpoints at six months including reinfarction,
CHF, death and ECG-confirmed ischemic episodes was
also conducted. Results in the renal group (Table 4) were
not significantly different from those shown in Figure 1 and
Table 3. In the nonrenal groups there was a trend towards
higher sensitivity and lower specificity for all markers (Table
4). However, the comparison of AUC for ROC curves was
virtually unchanged.
DISCUSSION
We evaluated the ability of serum cardiac troponin T and
troponin I concentrations in a group of patients with renal
insufficiency presenting with suspected acute coronary syn-
Table 2. Clinical Outcomes
Renal
(N 5 51)
Non-Renal
Troponin T
(N 5 102) p* Value
Non-Renal
Troponin I
(N 5 102) p* Value
In-Hospital outcomes (%) (%) (%)
Infarction/reinfarction 9.8 22.5 0.02 19.3 0.08
Death 3.9 0 0.11 0 0.11
Stroke 0 2.0 0.55 2.0 0.55
Recurrent ischemia 9.8 9.8 1.00 10.8 1.00
Bypass surgery 5.9 10.8 0.38 7.2 1.00
Congestive heart failure 15.7 3.9 0.02 4.8 0.06
Positive catheterization 21.6 37.2 0.23 31.3 0.25
Any adverse outcome 35.3 50.0 0.17 45.8 0.38
Outcomes at 6 months
Myocardial infarction 2.0 2.9 1.00 3.6 1.00
Death 15.7 4.9 0.11 6.0 0.08
Stroke 0 2.0 0.55 1.0 1.00
Recurrent ischemia 21.6 19.6 0.83 22.9 1.00
Bypass surgery 5.9 12.7 0.26 9.6 0.53
Congestive heart failure 23.5 6.8 0.007 8.4 0.02
Positive catheterization 25.5 38.2 0.14 32.5 0.44
Any adverse outcome 58.8 55.9 0.86 44.1 0.72
*Compared with renal group.
474 Van Lente et al. JACC Vol. 33, No. 2, 1999
Troponins in Patients With Renal Insufficiency and Chest Pain February 1999:471–8
dromes to predict adverse cardiac outcomes and compared
this performance with that observed for both markers in a
control group of patients without renal insufficiency
matched for their peak cTnT or cTnI value. Using a
case-matched approach strengthens the ability to assess the
relative diagnostic performance of biochemical markers in
relatively small patient groups. In order to evaluate the
comparative performance of the biochemical markers over
their full range of values, ROC curve analysis was employed.
The high degree of correlation of cTnT and cTnI values in
the groups in a matched study enhances the comparative
ROC analysis of the diagnostic information provided by
these markers (12).
Noncardiac factors that could affect cardiac troponin
values in patients with renal insufficiency. The finding of
detectable troponin concentrations in some sera of patients
with chronic renal disease has been attributed to noncardiac
causes. These patients, generally those with end-stage renal
disease requiring dialysis, routinely failed to exhibit evidence
for ischemic heart disease (7–9). These apparently false
positive values have been attributed to lack of assay speci-
ficity or to expression of cardiac troponin in skeletal muscle
(14,15). Similar conclusions had been reached previously to
explain apparently false positive CK-MB results in similar
patient groups (16). Unfortunately, most of these studies
were performed in the absence of evidence for active
coronary syndromes and the results are difficult to extrap-
olate to the symptomatic patient. One recent report of
patients with acute chest pain identified 7 of 773 patients
with positive cTnT and negative cTnI, six of which had
renal disease (17). Because renal disease was present,
these were considered false positive results.
We found little evidence that the false positive or false
negative rate of cTnT or cTnI was related to the magnitude
of renal insufficiency; there was no correlation of cTnT or
cTnI values with serum creatinine in patients without
adverse outcomes. It is possible that the length of time the
patients had renal disease or the degree of left ventricular
hypertrophy can affect the pattern of release of cTnT and
cTnI in these patients. There was also a tendency towards
less marked increase in troponin values after presentation in
the renal group. This finding could indicate a more stable
condition, cardiac or noncardiac, resulting in release of
troponins into the circulation.
Patients with renal disease are at risk for cardiac disease
(18) and our study group with renal insufficiency exhibited
a high prevalence of hypertension and history of myocardial
infarction. The risk in this population is also evident in the
relatively high incidence of adverse outcomes, 35% initially
and 59% at 6 months. Both the number of cardiac-related
risk factors and frequency of adverse outcomes was similar
in patients without renal disease matched for peak troponin
values. Thus, it is evident that the relative performance of
cTnT and cTnI in renal patients cannot be attributed to
differences in prior probability of adverse outcomes in this
patient group.
The spectrum of complications was somewhat different in
patients in the renal group compared with the nonrenal
group even though the peak release of troponins was
identical. The renal group exhibited more deaths and
CHF than the nonrenal group, and the latter was
statistically significant. Also, patients in the nonrenal
disease group tended to have a greater incidence of
myocardial infarctions.
Usefulness of cTnT and cTnI in risk stratification of
patients presenting with acute coronary syndromes and
renal disease. There have been several recommendations
regarding the appropriate troponin concentration threshold
to employ when attempting to risk stratify patients with
acute coronary syndromes. Unfortunately, most investiga-
tors have taken the simplistic approach of defining a single
Figure 1. Receiver operating characteristic curves for (A) cardiac
troponin T (cTnT) and (B) cardiac troponin I (cTnI) in predicting
initial hospitalization adverse events in patients with (dotted line)
and without (solid line) renal insufficiency. The lines represent
prognostic sensitivity and false positive rates at increasing thresh-
old values. The AUC and standard error are shown for each curve
and the upper-left inflection points are indicated by an arrow and
the corresponding sensitivity and specificity are shown in Table 3.
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threshold without evaluating markers over the full range of
values. Katus et al. used 0.5 mg/L in assessing unstable
angina patients using a first generation cTnT assay (19).
Using a more sensitive assay the same group evaluated cTnT
at a threshold of 0.2 mg/L for risk evaluation of similar
patients and found that it exhibited almost perfect sensitiv-
ity (0.97) and specificity (0.98) for predicting subsequent
myocardial infarction or death (20). More recently, a cTnT
threshold of 0.1 mg/L demonstrated a 0.43 sensitivity and
0.85 specificity for adverse 30-day outcomes in patients
presenting with ECG-documented acute myocardial isch-
emia (21). Troponin I values greater than 0.4 mg/L were
shown to predict a significantly higher risk of mortality (22).
As would be expected, risk has been shown to increase with
increasing cTnT or cTnI concentrations (21,22). Our
thresholds for both the renal and nonrenal groups were
optimized for overall accuracy from ROC curve analysis and
indicate that a higher cTnT threshold of 0.5 mg/L is needed
in patients with renal insufficiency for predicting in-hospital
outcomes compared with 0.1 mg/L for the non-renal pa-
tients. The net effect is a considerably lower sensitivity for
predicting adverse outcomes at the same specificity. The
same affect is seen for predicting 6 month outcomes albeit at
the same optimized threshold of 0.1 mg/L. Troponin I
exhibits a similar effect of decreased sensitivity in renal
patients although at a somewhat decreased specificity com-
pared with cTnT. This was observed for both in-house and
six month outcomes.
Comparison of troponin T, troponin I and CK-MB.
The direct comparison of cTnT and cTnI in study shows no
significant differences in marker performance in renal pa-
tients with suspected coronary syndromes. Therefore, the
advantage of one marker versus the other in this patient
group cannot be clearly delineated. Several previous studies
have concluded that cTnT is less specific than cTnI in
patients with renal disease, but our data do not support this
view. It is clear that both markers have a somewhat different
relationship to adverse outcomes in renal patients than they
do in nonrenal patients. Threshold adjustment can optimize
either sensitivity or specificity.
Creatine kinase MB could only be evaluated for prognos-
tic information for six month outcomes because CK-MB
values were used as part of the active clinical protocol during
the in-house phase of the clinical course. Creatine kinase
MB did not demonstrate decreased prognostic value in renal
patients. Neither cTnT nor cTnI was significantly better
than CK-MB at predicting outcomes in patients with renal
insufficiency. However, the value of CK-MB for indicating
risk of adverse outcomes in nonrenal patients was clearly
inferior to either cTnT or cTnI. Although there have been
reports of falsely increased CK-MB in patients with renal
disease with suspected acute coronary syndromes, the body
of literature is small.
Study limitations. The nonrenal groups were matched to
the renal group based on peak cTnT or cTnI values
observed during the sampling protocol. This study design
should maximally challenge the relative information pro-
vided by these markers. This approach also avoids the
problems of matching based on relatively small numbers of
certain demographic factors such as an admitting diagnosis
of myocardial infarction. However, it is clear that the
spectrum of cardiac disease and outcomes is not equivalent
Table 3. Sensitivity and Specificity of Biochemical Markers
Threshold
Renal Group Non-Renal Group
Sensitivity Specificity Sensitivity Specificity
In-house outcomes
cTnT 0.02 mg/L* 0.81 0.33 0.85 0.43
cTnT 0.10 mg/L† 0.43 0.63 0.60‡ 0.87‡
cTnT 0.50 mg/L 0.29‡ 0.87‡ 0.31 0.96
cTnI 0.35 mg/L* 0.33‡ 0.77‡ 0.67 0.63
cTnI 0.60 mg/L† 0.28 0.80 0.53 0.87
cTnI 1.00 mg/L 0.24 0.83 0.50‡ 0.93‡
Six month outcomes
cTnT 0.02 mg/L* 0.75 0.44 0.76 0.55
cTnT 0.10 mg/L† 0.45‡ 0.72‡ 0.56‡ 0.87‡
cTnI 0.35 mg/L* 0.33‡ 0.78‡ 0.55 0.61
cTnI 0.60 mg/L† 0.27 0.83 0.42 0.82
cTnI 1.00 mg/L 0.21 0.89 0.40‡ 0.90‡
MB 0.7 mg/L* 0.58 0.44 0.71 0.53
MB 5.0 mg/L† 0.39‡ 0.83‡ 0.52 0.73
MB 10.0 mg/L 0.21 0.94 0.37‡ 0.93‡
*Assay method limit of detection; †Assay threshold usually considered consistent with cardiac injury; ‡Sensitivity/specificity at
optimal test performance determined from ROC curve.
cTnT 5 cardiac troponin T; cTnI 5 cardiac troponin I; MB 5 creatine kinase MB isozyme.
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in the two groups and this could have affected comparative
performance of cardiac markers. It cannot be ruled out that
renal and nonrenal groups matched by admitting diagnosis
or history of hypertension, two factors significantly different
between groups, would demonstrate different relative utility
of cTnT or cTnI. The differences in the natural history of
cardiac disease in patients with renal insufficiency could lead
to altered patterns of troponin leakage. Nonetheless, the
study design did provide for assessment of this affect by
matching patients on the basis of troponin release.
It is possible that some of the differences in the ability of
cTnT and cTnI in predicting adverse events in patients with
renal insufficiency is due to assay performance. The assays
differ in their lower limits of detection and, in this case, the
cTnT assay is capable of detection at 0.02 mg/L while the
cTnI can detect 0.35 mg/L. The second generation cTnT
assay used here has been reported to have little cross-
reactivity to the skeletal muscle isoform of troponin T.
However, residual cross-reactivity of troponin T from non-
cardiac sources in patients with renal disease cannot be ruled
out although the lack of significant differences between
cTnT and cTnI make this unlikely. It is possible than other
cTnI assays could exhibit different diagnostic performance
in similar patient groups. Additionally, this study employed
batch analysis of troponin concentrations using plasma
stored at 270°C; any significant degradation of specimen
integrity during the storage period could also have affected
the relative performance of cTnI versus cTnT (24).
We matched a total of 51 patients with serum creatinine
values $20 mg/L with a corresponding control group from
a much larger cohort of patients. The discriminating power
of the study would have been enhanced with larger groups.
However, the incidence of patients presenting with sus-
pected acute coronary syndromes whose serum creatinine
concentrations are increased is a fraction of those with
normal serum creatinine concentrations and the logistics of
a larger study was not feasible. In addition, the incidence of
patients who were hemodialysis-dependent was relatively
small and, therefore, this study could not specifically address
the performance of cTnT in end stage renal disease sepa-
rately.
The assessment of 6 month outcomes was conducted by
phone survey while the in-house assessment was performed
by chart review and confirmation of appropriate ECG or
catheterization data. Although no positive angiographies
were performed after the initial outcome period, the inher-
ent confidence interval for the 6 month data can be assumed
to be slightly larger than that for the in-house outcomes.
We cannot determine whether this leads to an over or
underestimation of actual events. However, the relative
performance of cTnT, as well as cTnI, in both outcome
categories is consistent with a relatively accurate assessment
of 6 month outcomes.
Conclusions. The ability of cardiac troponin T and cardiac
troponin I to predict risk for subsequent adverse outcomes
in patients presenting with suspected acute coronary syn-
dromes is reduced in the presence of renal disease.
Figure 2. Receiver operating characteristic curves for predicting
adverse outcomes by 6 months for (A) cardiac troponin T (cTnT),
(B) cardiac troponin I (cTnI) and (C) creatine kinase MB
(CKMB). The dotted line represents the renal group and the solid
line the nonrenal group. The lines represent prognostic sensitivity
and false positive rates at increasing threshold values. The AUC
and standard error are shown for each curve and the upper-left
inflection points are indicated by an arrow and the corresponding
sensitivity and specificity are shown in Table 3.
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Table 4. Sensitivity and Specificity of Biochemical Markers for Predicting Ischemic Outcomes
by 6 months
Threshold
Renal Group Non-Renal Group
Sensitivity Specificity Sensitivity Specificity
cTnT 0.02 mg/L* 0.79 0.32 0.88 0.38
cTnT 0.10 mg/L† 0.48 0.73 0.64 0.78
cTnT 0.50 mg/L 0.28 0.91 0.36 0.93
cTnI 0.35 mg/L* 0.34 0.77 0.67 0.48
cTnI 0.60 mg/L† 0.28 0.82 0.59 0.67
cTnI 1.00 mg/L 0.24 0.86 0.57 0.73
MB 0.7 mg/L* 0.62 0.59 0.69 0.43
CK-MB 5.0 mg/L† 0.41 0.82 0.57 0.68
CK-MB 10.0 mg/L 0.20 0.91 0.45 0.88
*Assay method limit of detection; †Assay threshold usually considered consistent with cardiac injury.
cTnT 5 cardiac troponin T; cTnI 5 cardiac troponin I; MB 5 creatine kinase MB isozyme.
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